Valye reports for unlimited access

Cardinal Health, Inc. is a global healthcare services and products company providing pharmaceuticals, medical products, and related services to a broad range of healthcare providers and patients. The company operates two main segments: Pharmaceutical and Specialty Solutions, which distributes branded, generic, and specialty pharmaceuticals and provides pharmacy management and MSO services; and Global Medical Products and Distribution, which manufactures and distributes medical, surgical, and laboratory products across multiple geographies. Additional operations include nuclear and precision health solutions, at-home medical supplies, and logistics services. Fiscal 2026 saw revenue growth driven by branded and specialty pharmaceuticals and acquisitions of MSO platforms. The company manages significant opioid litigation settlements and invests in manufacturing and technology infrastructure. Capital structure includes a revolving credit facility and long-term debt, with active share repurchase programs.

Energy Focus, Inc. designs, manufactures, and sells energy-efficient LED lighting systems and advanced power solutions primarily for commercial and military maritime markets. Its product range includes LED retrofit kits, emergency backup LED tubes, military-grade LED fixtures, energy storage systems (ESS), Gallium Nitride (GaN) power supplies, and uninterruptible power supply (UPS) systems tailored for AI data centers. The company emphasizes product innovation, quality, and energy efficiency, with a focus on reducing flicker and improving occupant wellness. It operates a multi-channel sales strategy targeting enterprise end-users, contractors, and energy service companies, with a significant portion of revenue derived from U.S. Navy contracts and commercial customers in healthcare, education, and industrial sectors. The company is expanding its presence in Asia, particularly Taiwan and Japan, and is pursuing new markets in energy storage and AI data center power solutions. Manufacturing is a mix of in-house assembly and outsourced production, with supplier concentration risks noted. The company faces intense competition from larger and lower-cost manufacturers but seeks to differentiate through technology and customer focus.

Microbot Medical Inc. develops and commercializes the LIBERTY® Endovascular Robotic Surgical System, a robotic surgical device intended for endovascular procedures. The company shifted its focus from research and development to commercialization in 2025 and began a full U.S. launch of the LIBERTY system in April 2026. Manufacturing is outsourced to third-party partners, including Sanmina Corporation, to scale production and support cost reduction strategies. Microbot has limited operating history as a commercial-stage company and has not generated significant revenues from product sales through the end of 2025. The company reported revenue growth and new customers in Q2 2026 but continues to incur net losses. It funds operations primarily through equity offerings and grants and faces substantial costs associated with operating as a public company. Microbot's business depends heavily on the successful commercialization and market acceptance of the LIBERTY system, which requires regulatory approvals, manufacturing scale-up, reimbursement arrangements, and acceptance by medical professionals and payors. The company operates internationally, including in Europe and Israel, and faces risks related to geopolitical conditions and currency fluctuations.

BlueOne Technologies, Inc. is a Nevada-based fintech company that has transitioned from prepaid card program management to providing advanced payment infrastructure solutions globally. The acquisition of Millennium EBS Inc. expanded its offerings to include a Payment Hub and orchestration platform that streamlines multiple payment types, ISO 20022 migration and compliance services, and Remittance-as-a-Service for fintechs. The company also plans to launch BlueOne Pay, a platform enabling conversion of USDT stablecoin to USD for remittance purposes, targeting underbanked and digital asset users. BlueOne operates through strategic partnerships and focuses on markets in North America, Europe, Asia, and emerging regions such as South Asia, Middle East, and Africa. The company is publicly traded on the OTCQX market under the symbol BCRD and has a small team supplemented by experienced contractors.

Independence Power Holdings, Inc. is engaged in the deployment and operational management of battery energy storage systems (BESS) through its subsidiaries, including DBD Express and Kyma Batteries. The company acquired a fleet of 101 modified containerized BESS units from GridCore and provides services under an Asset Management Agreement with cooperative parties. It utilizes an embedded operating system and software platform to manage these assets at centralized rental yards and field sites. The company maintains related-party agreements for administrative services and leases property for operational use. Financially, the company reported no revenue but incurred a net loss in the latest quarter, with substantial current assets and a strong current ratio indicating liquidity [S1][S2].

Aprea Therapeutics, Inc. focuses on precision medicine oncology by developing small molecule inhibitors that target genetic mutations in cancer cells to selectively kill them while sparing healthy tissue. The company applies the synthetic lethality concept, targeting DNA damage response pathways to exploit vulnerabilities in cancer cells. Its pipeline includes APR-1051, a WEE1 kinase inhibitor in Phase 1 clinical trials for various solid tumors with specific genetic biomarkers, and ATRN-119, an ATR kinase inhibitor with a recommended Phase 2 dose, currently being evaluated for combination therapies. An early-stage DYRK1 inhibitor program is in preclinical development. Aprea retains worldwide rights to its candidates and may pursue strategic partnerships. The company has a strong liquidity position with over $41 million in cash and equivalents as of mid-2026 and continues to incur operating losses typical of clinical-stage biopharmaceutical companies.

Odysight.ai Inc. specializes in AI-powered visual monitoring solutions that deploy miniature vision-based sensors to monitor critical safety components in hard-to-reach and harsh environments. The company’s technology enables real-time condition-based monitoring and predictive maintenance by streaming visual data to an AI/ML processing unit and analyzing it on a secure cloud platform. This approach enhances safety, reduces downtime, and lowers maintenance costs across civil and defense sectors. The company’s solutions are integrated into aerospace platforms such as the AH-64 Apache and SH-60 Seahawk helicopters, UAVs, and industrial systems including elevator belts and mine trucks. Odysight.ai’s business model currently generates revenue primarily from initial system sales, with plans to expand recurring software subscription revenues. The company maintains a broad patent portfolio and a research and development team focused on advancing its technology. Sales efforts target aerospace and Industry 4.0 verticals globally, leveraging strategic partnerships and direct OEM engagements.

International Land Alliance Inc. operates in the real estate development sector, primarily focusing on residential and resort properties in Mexico and the United States. The company acquires land, develops infrastructure, constructs homes and commercial properties, and markets and sells these properties. Key projects include Rancho Costa Verde and Oasis Park Resort, where the company has reported sales and development progress. The company finances its operations through equity and debt offerings, including convertible promissory notes with warrants. Its business model relies on successful property development, sales, and capital raising to fund ongoing operations and growth.

THEGLOBE.COM, INC. was incorporated in 1995 and originally operated as an online community. In 2008, it sold its last operating business and became a shell company with no material operations or assets. Since then, it has had no revenue and no employees. The company’s expenses are limited to customary public company costs such as legal, audit, and administrative fees. Its majority stockholder, Delfin Midstream Inc., owns approximately 70.9% of the company and provides loans to fund its operations. The company’s common stock is delisted from NASDAQ and trades on the OTC market. As of June 30, 2026, the company had a net working capital deficit and reported net losses, with substantial doubt about its ability to continue as a going concern without additional funding [S1][S2].

Goldenwell Biotech, Inc. is a biotechnology company incorporated in 2019 with no subsidiaries and a fiscal year ending December 31. The company operates from a mailing address in Solon, Ohio, without conducting active operations at that location. It has developed a portfolio of five products, primarily polypeptide freeze-dried powders and solid tablets, which have completed marketing analysis, research and development, and production process setup stages. The company licenses technology and packaging designs from Australian Trefoil Health Technologies Pty Ltd and Ji Lin JZY Biotech Inc. under exclusive agreements covering global territories except China. Goldenwell Biotech does not own patents but protects its proprietary rights through trademarks, trade secrets, and contractual provisions. The company is not subject to known governmental regulations for its products and has no history of bankruptcy or similar proceedings.

CXApp Inc. delivers AI-powered employee experience solutions via its CXAI Platform, a cloud-based, mobile-first SaaS offering designed to improve workplace engagement, productivity, and operational efficiency. The platform integrates mobile and web applications, a core infrastructure layer for workflow automation, AI-enabled analytics, and agentic AI capabilities to support hybrid work environments. CXApp targets enterprise customers, including Fortune 1000 companies, across multiple industries. The company generates revenue primarily through recurring SaaS subscriptions and professional services for deployment and configuration. CXApp holds a portfolio of patents related to indoor navigation, 3D object detection, and wireless signal technologies. The company employs approximately 35 full-time staff and operates globally with a focus on the U.S. market [S1].

BIO KEY INTERNATIONAL INC is a Delaware-based company with publicly traded common stock on the Nasdaq Capital Market under the ticker BKYI. The company operates internationally with service, license, and hardware offerings across multiple regions including North America, Africa, EMESA, and Asia. The latest SEC filings provide detailed financial data through June 30, 2026, including liquidity metrics and net loss figures. The company completed a 1-for-10 reverse stock split effective April 30, 2026, adjusting its shares outstanding to approximately 1.44 million as of August 11, 2026.

Fluent, Inc. is a commerce media solutions provider that connects top-tier brands with highly engaged consumers through scalable digital marketing campaigns. The company operates two primary channels: Commerce Media Solutions, which delivers targeted advertising within e-commerce and digital media transaction flows on partner sites and mobile apps, and owned and operated digital media properties (O&O Sites). Commerce Media Solutions uses proprietary ad-serving technology integrated at key consumer moments, such as post-transaction on e-commerce platforms, to drive high-quality customer acquisition for advertisers and generate revenue for media partners under exclusive long-term contracts. Fluent also maintains a large proprietary database of first-party, self-declared user information collected through its O&O Sites, which it leverages to serve targeted advertisements and provide direct outreach capabilities to clients. The company divested its call center-supported performance marketplace business in early 2026. Revenue is primarily generated on a per click, lead, or action basis aligned with client acquisition cost targets. Fluent's strategic focus has shifted towards scaling Commerce Media Solutions, which represented approximately 63% of consolidated revenue in Q2 2026, reflecting growth from prior periods. The company faces challenges in its O&O Sites business due to regulatory compliance changes following an FTC inquiry, impacting traffic volume and revenue. Fluent continues to diversify traffic sources and expand its ad network beyond O&O Sites while managing seasonality and macroeconomic factors affecting client spending.

Envirotech Vehicles, Inc. operates as a diversified power-backed hardware technology company with core competencies in power management, electrification, and hardware integration. Its business is organized into four main segments: commercial electric vehicles, drone systems, medical supplies, and AI data infrastructure. The commercial EV segment offers Class 2 to 5 electric vehicles for fleet and institutional customers, assembled from semi-knocked-down kits sourced from OEMs in China, Taiwan, and Malaysia. The drone segment is developing heavy-lift drones for agricultural, fire suppression, and forestry applications, designed for U.S. manufacturing but not yet commercially available. The medical supplies segment, through Maddox Industries, manufactures medical products for government and institutional customers, supporting domestic supply chain resiliency. The AI data infrastructure segment, initiated in 2026, focuses on modular, power-backed computing platforms integrating power generation, thermal management, and high-performance CPUs and GPUs to support AI workloads. The company’s strategy emphasizes scalable infrastructure, margin durability, and selective expansion, with a recent operational shift to Houston, Texas, to leverage energy sector synergies. EVTV faces market challenges in the EV segment due to policy shifts and tariffs, while drone and AI infrastructure markets offer potential growth avenues. The company’s financials as of mid-2026 show net losses and liquidity constraints, reflecting ongoing investments and operational costs.

HeartBeam, Inc. is a medical technology company focused on transforming cardiac care through personalized insights enabled by its proprietary 3D ECG technology platform. The company’s flagship product, the HeartBeam System, is the first FDA-cleared cable-free ambulatory 12-lead ECG device that captures the heart’s electrical signals in three dimensions and synthesizes a standard 12-lead ECG. The system includes a credit card-sized device, a patient application, a physician portal, and cloud-based algorithms, supported by a 24/7 cardiologist review service. HeartBeam’s technology aims to provide high-fidelity cardiac monitoring outside healthcare facilities, addressing the growing need for ambulatory cardiac monitoring and early detection of cardiac conditions such as arrhythmias and coronary artery disease. The company is advancing commercialization efforts targeting concierge and preventive cardiology practices and is developing expanded indications including heart attack detection and an extended wear patch. HeartBeam’s clinical data supports diagnostic equivalence to standard 12-lead ECGs, and the company is building a data repository to enable AI-based screening and prediction algorithms. The company had 17 employees as of early 2026 and maintains a strong cash position with no revenue reported in 2025.

Livento Group, Inc. has evolved through multiple business phases since its incorporation in 2013, initially operating in jewelry wholesale, then cosmeceutical skincare based on stem cell technology, followed by real estate development, and currently focusing on entertainment production and AI-driven financial software. The company’s current primary operations are conducted through BOXO Productions, a subsidiary established in 2022, which produces and distributes movies and television content. BOXO finances projects through a combination of internal funds, loans, and external investors, typically retaining a minority interest in cash flows. Livento also offers proprietary AI software, Elisee, designed to assist investment entities in portfolio management by analyzing large data sets with neurological network algorithms. The company reported a strong liquidity position as of mid-2026 but continues to operate at a net loss. Its common stock is traded on the Pink Sheets and is controlled by the CEO through super-voting preferred shares [S1][S2].

Exyn Technologies, Inc. specializes in autonomous robotics and AI-driven mapping solutions. Its product portfolio includes the ExynAI software platform and the Nexys autonomous mapping platform, which serve commercial, mining, infrastructure, and government sectors. The company has a defense-focused subsidiary, Exyn Defense, which targets defense sustainment markets with AI autonomy solutions. Exyn has secured multiple contracts globally and collaborates strategically to enhance its autonomous robotics ecosystem.

GBT Technologies Inc. is a company operating in a rapidly evolving technology industry with a focus on AI-driven solutions and integrated circuit technologies. The company has a limited operating history and has not yet achieved profitability. It has developed a portfolio of intellectual property including patents for integrated circuits, AI-driven electronic design automation tools, and human vitals monitoring devices. GBT has formed subsidiaries such as Cube Wellness Technologies, which deploys AI-powered digital wellness machines, and Cube X Media, a digital media and content platform. The company is pursuing growth through strategic acquisitions and rebranding efforts. Financially, GBT Technologies has a significant accumulated deficit and stockholders' deficit, with liquidity ratios indicating limited current assets relative to liabilities. The company funds operations through equity and debt financing and plans to raise additional capital to support its business plan. GBT Technologies' common stock trades on the OTC marketplace under the ticker GTCH, characterized by limited liquidity and high volatility.

NEXTNRG, INC. is engaged in mobile fuel delivery services and the development and deployment of smart microgrid infrastructure, including EV charging stations and healthcare-focused microgrids. The company generates revenue from fuel sales, either as one-time transactions or through monthly memberships, recognizing revenue at delivery or over the membership cycle. It has expanded its operations geographically into markets such as Canada and Oklahoma and has executed long-term power purchase agreements to validate its scalable healthcare microgrid platform. Financially, the company reported $48.8 million in revenue for Q2 2026 but incurred a net loss of $6.6 million. Liquidity is constrained, with current liabilities significantly exceeding current assets, and the company has undertaken financial restructuring and merchant cash advance agreements to manage cash flow. NEXTNRG faces risks related to volatile fuel prices, competition, regulatory changes including the reduction of federal incentives for EV infrastructure, cybersecurity threats to its connected systems, and environmental and safety liabilities inherent in fuel transport.

Fennec Pharmaceuticals Inc. develops and commercializes PEDMARK®, the first and only FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets PEDMARQSI® in Europe through an exclusive licensing agreement with Norgine. PEDMARK® has demonstrated clinical efficacy in reducing hearing loss without compromising cancer treatment efficacy. Fennec's business model includes direct U.S. sales supported by a specialized field force and patient access programs, alongside licensing partnerships for international markets. The company holds multiple patents covering PEDMARK® formulation and use, with exclusivity protections extending to 2039. Fennec is also pursuing regulatory and commercial opportunities in Japan and supports investigator-initiated studies to expand PEDMARK®'s clinical use [S1][S2].

Allbirds, Inc. was founded in 2015 as a sustainable lifestyle brand specializing in footwear and apparel made from natural and recycled materials. The company operates as a public benefit corporation with a strong commitment to environmental conservation and social responsibility, evidenced by its B Corp certification and high recertification scores. Its product portfolio centers on footwear, supported by apparel offerings, all designed for comfort, sustainability, and longevity. Distribution is primarily through a digitally-led direct-to-consumer model, complemented by selective wholesale and international distributor partnerships. Manufacturing is concentrated in Vietnam for footwear and in several countries for apparel, with a focus on quality and sustainability. In 2026, Allbirds closed its remaining full-price U.S. retail stores to focus on e-commerce and partnerships. Recently, the company has pivoted away from footwear to focus on AI technology under the NewBird AI brand, marking a significant strategic shift.

Ovid Therapeutics Inc. focuses on developing small molecule therapies for brain disorders characterized by neuronal hyperexcitability, including epilepsy and psychosis. The company’s strategy involves targeting fundamental biological mechanisms to restore neuronal balance, aiming to improve efficacy and safety over existing treatments. Its diversified pipeline includes five clinical-stage programs addressing drug-resistant seizures, developmental epileptic encephalopathies, and psychoses related to Parkinson’s disease, Lewy body dementia, and schizophrenia. Ovid’s R&D approach leverages multiple mechanisms of action and small molecule versatility, supported by strategic business development and academic collaborations. The company’s financial position as of mid-2026 shows strong liquidity but ongoing operating losses, reflecting its early-stage development status and lack of commercial products.

Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, multiplexed-engineered cellular immunotherapies derived from human induced pluripotent stem cells (iPSCs). The company engineers clonal master iPSC lines to produce uniform T-cell and natural killer (NK) cell therapies incorporating novel synthetic controls of cell function. This approach aims to overcome limitations of autologous and donor-derived cell therapies by enabling scalable, cost-effective manufacturing and broad patient accessibility. Fate's proprietary platform is supported by a large intellectual property portfolio and a fully integrated GMP manufacturing facility. The company's pipeline includes multiple iPSC-derived CAR T-cell and CAR NK cell product candidates targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis, as well as solid tumors. Clinical development programs include FT819, the first iPSC-derived CAR T-cell candidate in clinical trials, and next-generation candidates FT825, FT836, and FT839 incorporating multiple synthetic controls to enhance safety, efficacy, and patient reach. Regulatory designations and approvals support ongoing clinical trials in the US, UK, and EU. The company reported a net loss for the quarter ended June 30, 2026, with a strong liquidity position.

enCore Energy Corp. is an exploration stage uranium extraction company incorporated in British Columbia and operating primarily in the United States. The company focuses on domestic uranium production using proven in-situ recovery (ISR) technology, which is environmentally responsible and cost-efficient. enCore owns three of the ten licensed ISR Central Processing Plants (CPPs) in the U.S., all located in Texas, including the Rosita and Alta Mesa projects where uranium extraction commenced in 2023 and 2024 respectively. The company also holds exploration stage projects in South Dakota (Dewey Burdock), Wyoming (Gas Hills and Juniper Ridge), and New Mexico. enCore has established multi-year uranium sales contracts with major U.S. utilities, employing a strategy to balance market exposure with price floors and ceilings. The company is engaged in optimizing operations, expanding extraction capacity, and rationalizing its asset base through divestments. It faces competition from larger uranium producers and geopolitical risks affecting uranium supply chains.

Founded in 2006 and headquartered in Austin, Texas, YETI Holdings, Inc. designs, retails, and distributes premium outdoor products including coolers, drinkware, bags, and outdoor living items. The company operates globally with a focus on high-performance, durable products that serve diverse outdoor pursuits. YETI sells through a balanced omni-channel approach comprising wholesale partnerships with major retailers and a direct-to-consumer channel including websites, Amazon Marketplace, and retail stores. The product portfolio is organized into Coolers & Equipment, Drinkware, and Other categories, with ongoing innovation and expansion across these lines. YETI manages a global supply chain with third-party manufacturers and logistics providers, emphasizing quality control and supply discipline. The company competes in a fragmented market with established and emerging brands, leveraging its strong brand, intellectual property, and customer loyalty.

Gyrodyne, LLC is a New York limited liability company managing a portfolio of medical office and industrial properties primarily located in Suffolk and Westchester Counties, New York. The company’s business model involves managing leased properties where tenants reimburse many operating costs, pursuing entitlements to increase development flexibility and property values, and ultimately selling these assets. Gyrodyne intends to dissolve after disposing of all real estate assets, settling liabilities, and distributing remaining proceeds to shareholders. The company’s portfolio includes the Cortlandt Manor property with a medical center and the Flowerfield property with a multi-tenant industrial park. Legal proceedings related to subdivision and entitlement approvals for Flowerfield are ongoing, with appeals in process. Gyrodyne has entered into a purchase agreement for a significant parcel of Flowerfield contingent on approvals. The company is actively marketing remaining properties and may consider acquisition offers for itself. As of mid-2026, Gyrodyne holds cash reserves and is managing liquidity to fund ongoing entitlement and liquidation efforts. The CEO is the only full-time employee, with retention measures in place. The company faces risks related to legal challenges, timing and success of sales, and key personnel retention.

X-Energy, Inc. focuses on the design, development, and commercialization of advanced nuclear reactor technology, specifically the Xe-100 small modular reactor (SMR). The company is also developing fuel fabrication facilities to support its reactor technology. As of mid-2026, X-Energy has not yet delivered any commercial reactors and is in the design and development phase, with first commercial deployments planned for the early 2030s. The business model includes revenue from government contracts, licensing, technology fees, project planning, construction support, and fuel supply services. The company operates in a capital-intensive environment requiring substantial financing and government support.

Jones Soda Co. develops, produces, markets, and distributes premium beverages primarily in the United States and Canada. The company sells its products through a network of independent distributors (direct store delivery channel) and national and regional retail accounts, including grocery stores, convenience stores, restaurants, and other independent accounts. The company operates under the trademarked brand name "Jones Soda Co." and focuses on premium beverage offerings. Its distribution channels include both direct store delivery and national accounts with large retailers. The company maintains operations primarily in the US and Canadian markets [S1].

Quality Industrial Corp. is an industrial energy company focused on the liquefied petroleum gas (LPG) sector through its 51% ownership of Al Shola Al Modea Gas Distribution L.L.C., based in Dubai, UAE. Al Shola Gas offers a broad range of LPG-related services including system design, installation, maintenance, and supply of LPG in both bulk and cylinder formats. The company serves a diverse customer base across residential, commercial, and industrial sectors primarily in Dubai and expanding into other northern emirates. The business model includes both one-time engineering and installation revenues as well as recurring revenues from utility services and LPG supply. QIND has undergone ownership changes with a significant acquisition by Fusion Fuel Green PLC in late 2024, with plans for a merger. Financially, the company reported a net loss and limited liquidity as of mid-2026.

Launchpad Cadenza Acquisition Corp I is a Cayman Islands exempted blank check company formed in June 2025 to pursue a Business Combination with one or more businesses, primarily targeting technology and software infrastructure companies in blockchain, fintech, and digital assets sectors. The company completed its IPO in December 2025, raising $230 million, which is held in a trust account. It has not yet identified a Business Combination target and has no operating revenues. The management team and advisors have extensive experience in SPAC transactions and fintech-related investments. The company must complete a Business Combination by December 2027 or liquidate.

Snow Rothschild Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company completed its IPO, raising $226 million placed in a Trust Account to be used for its initial Business Combination. As of the latest SEC filing, the company has not announced a target for the Business Combination. The company’s financials show a net loss for the recent quarter and strong liquidity ratios, reflecting its current status as a SPAC prior to completing a business combination.

NexPoint Real Estate Finance, Inc. operates in the real estate finance sector, engaging in activities related to real estate investment and financing. The company maintains liquidity with cash and equivalents totaling approximately $6.38 million as of mid-2026. It communicates regularly with investors through earnings calls and public disclosures, providing updates on financial performance and operational status.

Classover Holdings, Inc. delivers comprehensive online live courses for K-12 students through its subsidiary Class Over Inc. The company’s curriculum spans multiple subjects and is designed to foster academic achievement and lifelong skills such as creativity and critical thinking. Its proprietary cross-platform technology supports interactive and adaptive learning environments accessible across devices. The platform integrates AI-driven analytics to personalize education based on student performance data. The company employs over 1,000 rigorously selected educators to maintain instructional quality. Additionally, Classover has integrated a digital asset treasury strategy focused on blockchain assets like Solana to support capital efficiency and future product innovation. The company completed a reverse stock split in March 2026 and has engaged in equity and convertible note financings. As of mid-2026, it reported modest revenue and a net loss, with strong liquidity.

Global Water Resources, Inc. operates 39 regulated water, wastewater, and recycled water utilities primarily in metropolitan Phoenix and Tucson, Arizona. The company serves over 121,000 people and approximately 40,000 homes within ACC-regulated service areas. Its business model centers on Total Water Management, which integrates water recycling, reuse, advanced metering, and regional planning to manage scarce water resources sustainably. GWRS has established partnerships with municipalities and developers to support its conservation and infrastructure strategies. The company’s utilities generate predictable rate-regulated cash flows under ACC oversight. Advanced technologies such as SCADA and AMI are widely deployed to improve operational efficiency and customer service. The company’s financials as of mid-2026 show positive net income and moderate liquidity ratios.

Armada Acquisition Corp. II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in October 2024. Its business model centers on raising capital through an IPO and private placements to fund a future business combination with an unspecified target. The company completed its IPO in May 2025, raising gross proceeds of $230 million, with additional private placement proceeds of $7.1 million. These funds are held in a trust account invested in U.S. government securities until a business combination is completed or the funds are returned to shareholders upon liquidation. The company has not yet completed a business combination but has entered into a Business Combination Agreement with entities including PubCo and Ripple, outlining a plan for mergers that would result in PubCo becoming publicly traded. The New Sponsor acquired control of the company in August 2025 and holds all equity interests previously held by the Original Sponsor. The company’s securities trade on Nasdaq under multiple symbols representing units, Class A shares, and warrants. The company maintains office space in Miami, Florida, paid for by the New Sponsor. As of June 30, 2026, the company reported net income of approximately $1.63 million and current assets of $177,850 against current liabilities of $5.47 million, reflecting a low liquidity position. The company has not paid dividends and does not intend to do so prior to completing its initial business combination.

Newbury Street II Acquisition Corp is a Special Purpose Acquisition Company (SPAC) incorporated in June 2024 with the purpose of effecting a Business Combination. The company completed its IPO in November 2024, raising approximately $179 million including private placements, with funds held in a Trust Account. It has no operating revenues and is focused on identifying and acquiring one or more private companies with strong unit economics, growth potential, and capable management teams. The company offers an alternative route for private companies to become publicly listed through a Business Combination rather than a traditional IPO. The management team has significant experience in investment and operations, aiming to leverage their network and expertise to identify suitable targets. The company must complete its Business Combination by November 2026 or face liquidation. As of June 2026, the company reported limited liquidity and a net income of $311,304. Recent developments include progress toward a Business Combination with FORT Robotics and new board appointments to strengthen expertise.